1. Home
  2. NRIX vs CYD Comparison

NRIX vs CYD Comparison

Compare NRIX & CYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$19.26

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo China Yuchai International Limited

CYD

China Yuchai International Limited

HOLD

Current Price

$42.62

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRIX
CYD
Founded
2009
1951
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.3B
IPO Year
2020
1994

Fundamental Metrics

Financial Performance
Metric
NRIX
CYD
Price
$19.26
$42.62
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
1
Target Price
$29.08
$60.00
AVG Volume (30 Days)
1.5M
139.1K
Earning Date
02-12-2026
02-24-2026
Dividend Yield
N/A
1.23%
EPS Growth
N/A
40.10
EPS
N/A
1.66
Revenue
$83,687,000.00
$3,159,401,156.00
Revenue This Year
$59.40
$41.12
Revenue Next Year
N/A
$6.93
P/E Ratio
N/A
$26.02
Revenue Growth
48.32
17.99
52 Week Low
$8.18
$9.90
52 Week High
$22.50
$45.93

Technical Indicators

Market Signals
Indicator
NRIX
CYD
Relative Strength Index (RSI) 57.80 65.94
Support Level $17.97 $35.28
Resistance Level $19.92 $45.93
Average True Range (ATR) 0.96 1.62
MACD -0.12 0.77
Stochastic Oscillator 76.56 67.26

Price Performance

Historical Comparison
NRIX
CYD

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About CYD China Yuchai International Limited

China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.

Share on Social Networks: